Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Payables (2017 - 2025)

Serina Therapeutics' Payables history spans 8 years, with the latest figure at $2.7 million for Q3 2025.

  • For Q3 2025, Payables rose 61.12% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $2.7 million, up 61.12%, while the annual FY2024 figure was $744000.0, 28.28% up from the prior year.
  • Payables for Q3 2025 was $2.7 million at Serina Therapeutics, up from $1.7 million in the prior quarter.
  • Across five years, Payables topped out at $4.0 million in Q1 2024 and bottomed at $161000.0 in Q2 2022.
  • The 5-year median for Payables is $1.1 million (2022), against an average of $1.2 million.
  • The largest annual shift saw Payables tumbled 88.35% in 2021 before it soared 496.89% in 2023.
  • A 5-year view of Payables shows it stood at $193000.0 in 2021, then surged by 194.3% to $568000.0 in 2022, then rose by 2.11% to $580000.0 in 2023, then rose by 28.28% to $744000.0 in 2024, then surged by 267.07% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Payables are $2.7 million (Q3 2025), $1.7 million (Q2 2025), and $1.2 million (Q1 2025).